All Updates

All Updates

icon
Filter
Partnerships
IBM and Boehringer Ingelheim partner to discover accelerated antibodies using AI-based FMs
Foundation Models
Nov 28, 2023
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Yesterday
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Yesterday
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Yesterday
Partnerships
Climeworks partners with Terraset to enable philanthropic support for carbon removal
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Funding
8 Rivers secures investment from JX Nippon to commercialize DAC technology
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Sep 17, 2024
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Sep 17, 2024
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Sep 17, 2024
Foundation Models

Foundation Models

Nov 28, 2023

IBM and Boehringer Ingelheim partner to discover accelerated antibodies using AI-based FMs

Partnerships

  • IBM has partnered with Boehringer Ingelheim, a group of pharmaceutical companies that focuses on prescription medicines and animal health, to expedite antibody discovery through in-silico methods, aiming to identify antibodies for diseases like cancer, autoimmune disorders, and infections.

  • IBM’s foundation model (FM) technologies assist in generating antibody candidates by analyzing disease-relevant information, enhancing the efficiency and quality of the discovery process.

  • The collaboration intends to advance drug discovery by creating a digital ecosystem, leveraging IBM's AI models—which have previously predicted properties of small molecules—for designing novel biologics and proteins.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.